ImpediMed Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
3,521.00
4,844.00
5,791.00
5,766.00
4,797.00
Cost of Goods Sold (COGS) incl. D&A
6,284.00
10,957.00
16,789.00
19,111.00
18,863.00
Gross Income
2,763.00
6,113.00
10,998.00
13,345.00
14,066.00
SG&A Expense
5,239.00
9,032.00
15,182.00
16,847.00
15,848.00
EBIT
8,002.00
15,145.00
26,180.00
30,752.00
30,623.00
Non Operating Income/Expense
10.00
12.00
2,304.00
39.00
215.00
Pretax Income
7,935.00
15,050.00
28,328.00
30,424.00
29,980.00
Income Tax
-
253.00
2,348.00
2,853.00
2,806.00
Consolidated Net Income
7,935.00
14,797.00
25,980.00
27,571.00
27,174.00
Net Income
7,935.00
14,797.00
25,980.00
27,571.00
27,174.00
Net Income After Extraordinaries
7,935.00
14,797.00
25,980.00
27,571.00
27,174.00
Net Income Available to Common
7,935.00
14,797.00
25,980.00
27,571.00
27,174.00
EPS (Basic)
0.04
0.06
0.08
0.07
0.07
Basic Shares Outstanding
200,989.60
268,288.90
319,882.60
374,699.60
377,041.80
EPS (Diluted)
0.04
0.06
0.08
0.07
0.07
Diluted Shares Outstanding
200,989.60
268,288.90
319,882.60
374,699.60
377,041.80
EBITDA
7,820.00
14,963.00
25,976.00
30,480.00
30,163.00
Other Operating Expense
-
-
-
560.00
709.00
Non-Operating Interest Income
57.00
83.00
156.00
367.00
428.00

About ImpediMed

View Profile
Address
50 Parker Court
Pinkenba Queensland (QLD) 4008
Australia
Employees -
Website http://www.impedimed.com
Updated 07/08/2019
ImpediMed Ltd. engages in the development and distribution of medical devices using bioimpedance spectroscopy technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases. It operates through the Medical and Test and Measurement segments. The Medical segment supplies non-invasive medical devices to two under-served markets: aiding in the subclinical assessment of individuals at risk of secondary lymphoedema; and the monitoring of body composition and hydration.